NCT03546465View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

July 15, 2019

Study Completion Date

July 15, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

ropeginterferon alfa-2b

6 subjects in each cohort will receive a single dose by subcutaneous injection

Trial Locations (1)

3004

Nucleus Network Limited, Melbourne

Sponsors

Collaborators (1)

PharmaEssentia
All Listed Sponsors
collaborator

PharmaEssentia

INDUSTRY

lead

PharmaEssentia Japan K.K.

INDUSTRY